Sarglitazar Approval Status
Sarglitazar is NOT approved by the FDA for hypercholesterolemia or fatty liver disease in the United States. The drug label evidence provided 1 contains only generic storage and safety information without any FDA-approved indications listed, confirming the absence of U.S. regulatory approval for these conditions.
Regulatory Context
The major U.S. and international guidelines for managing hypercholesterolemia and NAFLD/NASH do not include sarglitazar in their treatment algorithms:
For hypercholesterolemia: The 2022 ACC Expert Consensus 2 comprehensively lists approved nonstatin therapies (ezetimibe, PCSK9 inhibitors, bempedoic acid, inclisiran) but makes no mention of sarglitazar, indicating it is not recognized as a standard treatment option in the U.S.
For fatty liver disease: The 2021 KASL guidelines 3, 2018 AASLD guidance 4, 2012 AGA/AASLD/ACG guideline 5, and 2022 British guidelines 6 all focus on statins, vitamin E, pioglitazone, and GLP-1 agonists. None recommend sarglitazar as a treatment option.
Regional Approval
Sarglitazar has been approved in India since 2013 for diabetic dyslipidemia 7. Research studies from India demonstrate its effects on:
- Reducing triglycerides and improving lipid profiles 8, 7, 9
- Improving liver enzymes (ALT) and insulin resistance 7, 9, 10
- Reducing hepatic steatosis (CAP scores) and liver stiffness 7, 11
However, these are primarily small observational studies and pilot trials from a single geographic region, not the large-scale randomized controlled trials with hard clinical endpoints (mortality, cardiovascular events, liver-related outcomes) required for FDA approval.
Clinical Implications
If you practice in the United States or regions following FDA/EMA guidelines, sarglitazar is not an available treatment option. For managing these conditions, use:
For Hypercholesterolemia:
- First-line: Statins 2
- Add-on therapy: Ezetimibe (reduces LDL-C by 18-25%) 2
- High-risk patients: PCSK9 inhibitors 2
For NAFLD/NASH:
- Cardiovascular risk reduction: Statins are safe and recommended for dyslipidemia in NAFLD patients 3, 5, 3
- NASH treatment in non-diabetics: Vitamin E 800 IU/day 3, 4
- NASH treatment with diabetes: Pioglitazone 4
- Weight loss and lifestyle modification remain foundational 6
Important caveat: While research suggests saroglitazar may have beneficial effects on metabolic parameters 8, 7, 9, 10, 11, 12, the absence of FDA approval means it lacks the rigorous safety and efficacy validation required for routine clinical use in most Western healthcare systems.